WALTHAM, Mass.--(EON: Enhanced Online News)--Glytec today announces another notice of allowance from the United States Patent and Trademark Office (USPTO) for its eGlycemic Management System® (eGMS®), a modularized software-as-a-service solution used by hospitals and health systems for personalized insulin dosing, enterprise glucose surveillance, performance-driven analytics, and more. This latest notice comes on the heels of three others received this past September -- adding to U.S. Patent 9,233,204 and U.S. Patent 9,171,343 -- bringing the total number of patents held by Glytec to six, with more than 50 U.S. and international patents pending.
“This is a significant milestone for Glytec in that it strengthens and extends our intellectual property position, and broadens our long-term protections.”
“We are pleased the USPTO views eGMS® as a unique and innovative asset in the management of insulin therapy for inpatients and outpatients,” says Bob Leonard, President and CEO. “This is a significant milestone for Glytec in that it strengthens and extends our intellectual property position, and broadens our long-term protections.”
The newly allowed application that will soon issue as a patent recites, among other things, automated methods and systems to:
- Safely and effectively transition from intravenous to subcutaneous insulin therapy. This includes algorithms and calculations for the transition from intravenous to subcutaneous insulin therapy that account for infusion rates, blood glucose descent velocity, blood glucose threshold ratios, prescribed targets, solid food consumption, estimated and actual grams of carbohydrate intake, carbohydrate-to-insulin ratios, meal bolus insulin doses, and successive sub-interval meal times.
- Warn if a transition from intravenous to subcutaneous insulin therapy may be premature. This includes the display of a warning message to end users and blocking of the transition from intravenous to subcutaneous insulin therapy when the current blood glucose measurement is outside of a stability target range or when the current blood glucose measurement is within a stability target range for less than a threshold stability period of time.
- Determine the total daily dose (TDD) of insulin. This includes algorithms and calculations for determining recommended subcutaneous doses comprising a daily basal insulin and a daily meal bolus insulin as an apportioning of the TDD; also, communications regarding recommended doses directed to an injection device or a computer display.
- Integrate blood glucose meter technologies, insulin dosing technologies and insulin administration technologies. This includes communications and data exchanges between technologies (devices) for blood glucose measurement, insulin dosing and insulin infusion as well as instructions for transitory and non-transitory storage.
Robby Booth, Senior Vice President Research and Development, adds, “Our IP strategy is focused on developing unparalleled technologies that address the needs of people with diabetes, whether they’re receiving care in a hospital or they’re receiving care at home through a telehealth or population health program. Making sure their glucose is well controlled through an optimal insulin regimen is one of the single most important variables in combatting risks of morbidity and mortality, and in reducing the overall cost of care.”
Glytec has partnered with hospitals and health systems across the country on more than 55 research studies to date, all of which demonstrate unequivocally that eGMS® improves both clinical and financial outcomes. This includes reductions in hyperglycemia, hypoglycemia, A1c levels, average lengths of stay and 30-day readmissions. Hospitals using eGMS® have realized an annualized savings as high as $10,000 per licensed bed.
Founded in 2006, Glytec is a leading innovator in the care of patients with diabetes, pioneering the way hospitals and health systems use technology to ensure optimal glucose control and reduce the frequency, risks and costs of hyperglycemia and hypoglycemia. The company’s comprehensive eGlycemic Management System® (eGMS®) centers on the only FDA-cleared insulin dosing solution able to support intravenous and subcutaneous therapy for adult and pediatric populations across the entire care continuum. eGMS® offers personalized clinical decision support that seamlessly integrates with EMR systems and connected devices for streamlined use in all inpatient and outpatient settings, with the unique ability to support at-home, prescriber-directed care managed through telehealth, population health and other value-based programs. eGMS® employs a cloud-hosted software-as-a-service (SaaS) model, allowing for rapid implementation and anytime, anywhere access. Efficacy of eGMS®, including its ability to substantively improve clinical and financial outcomes, has been validated by more than 55 research studies. Results have included dramatic reductions in lengths of stay, readmissions and A1c levels. Glytec currently holds six U.S. patents and has more than 50 U.S. and international patents pending. The company has offices in Waltham, Massachusetts and Greenville, South Carolina. For more information, visit www.glytecsystems.com.